Iambic Therapeutics, Inc. (IAM) fair value analysis
Nasdaq · Updated 2026-10-26
IAM price how computed
Valuation status
No fair-value estimate yetIAM has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for IAM yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $14.26
- Sector
- Healthcare
- Market cap
- $676M
- Shares outstanding
- 47.4M
Last price is the 2026-10-23 close; the chart runs through 2026-10-23.
Iambic Therapeutics, Inc. is a biopharmaceutical company that develops treatments for fibrotic diseases and other conditions. The company operates in the United States and focuses on advancing its pipeline of therapeutic candidates through clinical development.
Fundamentals how computed
- Market cap
- $676M
- Shares outstanding
- 47.4M
What our data shows for IAM
- IAM is covered in the Nasdaq universe of TickrTrends' weekly Forward Fair Value refresh.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- IAM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the IAM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-26 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is IAM stock undervalued?
TickrTrends has no fair-value estimate for IAM yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is IAM's TickrTrends verdict?
IAM is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
Is IAM overbought or oversold?
TickrTrends does not currently publish an RSI signal for IAM.